Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies

JAMA Intern Med. 2020 Sep 1;180(9):1145-1146. doi: 10.1001/jamainternmed.2020.2402.
No abstract available

MeSH terms

  • Access to Information
  • Antimalarials / pharmacology
  • Betacoronavirus
  • COVID-19
  • Chloroquine / pharmacology*
  • Coronavirus Infections* / drug therapy
  • Coronavirus Infections* / epidemiology
  • Drug Approval / legislation & jurisprudence*
  • Drug Repositioning* / methods
  • Drug Repositioning* / standards
  • Drug Repositioning* / trends
  • Evidence-Based Medicine
  • Humans
  • Hydroxychloroquine / pharmacology*
  • Pandemics*
  • Pneumonia, Viral* / drug therapy
  • Pneumonia, Viral* / epidemiology
  • Prior Authorization* / legislation & jurisprudence
  • Prior Authorization* / trends
  • SARS-CoV-2

Substances

  • Antimalarials
  • Hydroxychloroquine
  • Chloroquine

Supplementary concepts

  • COVID-19 drug treatment